The Innovative Fresh Start Private Implant* Procedure

Decorative Images

Fresh Start Private (FSP) is the only alcohol treatment program in the world to offer a single-administration, long-acting, naltrexone implant™* procedure that has been approved for use by a regulatory body.** This novel and highly effective* treatment delivers target therapeutic levels of naltrexone for an average of approximately 200 days and up to as many as 390 days*** via an innovative implant procedure developed by Dr. George O’Neil. Once implanted, the O'Neil Naltrexone Implant eliminates the need for the patient to choose or remember to take naltrexone on a regular basis.

In a minimally invasive, outpatient procedure, trained medical doctors at an independent clinic which is part of the FSP network in Australia insert a specially formulated, biodegradable naltrexone implant just beneath the skin below the patient’s lower abdominal area. The procedure is rapid and requires only local anesthetic. Patients are awake during the short procedure and have reported minimal to no physical discomfort.

In nearly every instance, patients are released the same day as the procedure and allowed to return to their recovery suites with their accompanying recovery partner. A recovery partner, while often a spouse or significant other, can be any capable adult selected by the patient.

Patients have typically reported complete freedom from alcohol cravings within hours of the procedure and a return to normal physical activity by the next day. The rapid-onset of the medication, and the short recovery period allows patients and their loved ones to immediately begin healing and working together towards an alcohol-free life. To facilitate a complete and permanent recovery, patients and their families and friends immediately initiate both the On-Purpose® Fresh Start Coaching Program and the Family and Friends Rebuilding Retreat.

* The FSP naltrexone formulation and the implant procedure have been approved as safe and effective under the Special Access Scheme by the Australian Therapeutics Goods Administration. The FSP naltrexone formulation and the implant procedure have not been approved by the FDA. Treatment with the FSP naltrexone formulation and the implant procedure is not available in the United States.

** FSP does not render medical advice or services. Individuals should consult their physicians or other competent medical professionals to determine if FSP's program is right for them. Medical services in Australia are provided by Dr. George O'Neil and physicians working with him.

*** Addiction Biology (March 2004) 8, 65-70. G.K. Husle, D.E. Arnold-Reed. G. ONeil, C-T. Chan & R.C. Hansson